An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
Trial details
- Registry ID
- NCT05645432
- Phase
- Phase 2
The FDA approved Brexanolone (Allopregnanolone) on 19 Mar 2019.
Drug identity checked against registry records
Also recorded as Allopregnanolone; SAGE-547; ZULRESSO®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| An Open-Label Study Evaluating Brexanolone in Adults With TinnitusNCT05645432 | SUPN | Phase 2 | Completed | 2023-11-21Actual |
| A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)NCT03665038 | SUPN | Phase 3 | Completed | 2021-01-08Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2019-03-19Day | Brexanolone | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA211371", "applicant_as_listed_by_fda": "SAGE THERAP SUPERNUS", "brand_names": ["ZULRESSO"], "active_ingredients": ["BREXANOLONE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20190319", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |